SEC Form 4 · accession 0001209191-17-037324
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason A Keyes
Officer — SVP, Chief Financial Officer
Period of report
May 31, 2017
Accepted (ET)
Jun 2, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 31, 2017 | A | 557 | $1.55 | A | 3,031 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.